Onconova Therapeutics Stock Cash Flow From Operations
| ONTXDelisted Stock | USD 1.02 0.04 3.77% |
Onconova Therapeutics fundamentals help investors to digest information that contributes to Onconova Therapeutics' financial success or failures. It also enables traders to predict the movement of Onconova Stock. The fundamental analysis module provides a way to measure Onconova Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Onconova Therapeutics stock.
Onconova |
Onconova Therapeutics Company Cash Flow From Operations Analysis
Onconova Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Onconova Therapeutics Cash Flow From Operations | (17.93 T) |
Most of Onconova Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Onconova Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Onconova Therapeutics has (17.93 Trillion) in Cash Flow From Operations. This is 3401035.41% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The cash flow from operations for all United States stocks is significantly higher than that of the company.
Onconova Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Onconova Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Onconova Therapeutics could also be used in its relative valuation, which is a method of valuing Onconova Therapeutics by comparing valuation metrics of similar companies.Onconova Therapeutics is currently under evaluation in cash flow from operations category among its peers.
Onconova Fundamentals
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (89.28) % | |||
| Current Valuation | (4.56 M) | |||
| Shares Outstanding | 21 M | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 7.95 % | |||
| Number Of Shares Shorted | 20.7 K | |||
| Price To Earning | (0.87) X | |||
| Price To Book | 1.43 X | |||
| Price To Sales | 92.50 X | |||
| Revenue | 226 B | |||
| Gross Profit | 226 K | |||
| EBITDA | (20.3 T) | |||
| Net Income | (18.95 T) | |||
| Cash And Equivalents | 46.53 M | |||
| Cash Per Share | 2.23 X | |||
| Debt To Equity | 1.26 % | |||
| Current Ratio | 7.43 X | |||
| Book Value Per Share | 0.69 X | |||
| Cash Flow From Operations | (17.93 T) | |||
| Short Ratio | 0.19 X | |||
| Earnings Per Share | (0.96) X | |||
| Target Price | 8.33 | |||
| Number Of Employees | 16 | |||
| Beta | 1.35 | |||
| Market Capitalization | 20.9 M | |||
| Total Asset | 22.68 T | |||
| Retained Earnings | (482.63 T) | |||
| Working Capital | 31.3 M | |||
| Current Asset | 23.18 M | |||
| Current Liabilities | 7.61 M | |||
| Z Score | -32.73 | |||
| Net Asset | 22.68 T |
About Onconova Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Onconova Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Onconova Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Onconova Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |